Thats an interesting point you touch on Edgck. Desire to...

Thats an interesting point you touch on Edgck. Desire to execute. l assume you are referring to the management of PIQ. Something thats a niggling thing in the back of my mind is a lack of business accumen at the top which may stiffle this companies commercial development. l only say that based on a number of trading halts that were rather mundane. l agree that Covid has delayed progress for many Biotech Companies, PIQ included, but at this mature development stage of the Company, lots of things should be falling into place. The plan to greatly increased sales revenue should be obvious to all share holders and new investors wanting to jump on board just before this thing really takes off. Instead, the SP has been decimated and may continue to fall to Lord knows what level. While this is happening, management looks like they are clueless by not offering up some kind of media release to calm the market and restore confidence in the share. Yes, l firmley believe management is duty bound to do this because good governance is one of their responsibilities. Being quiet does the opposite. It spooks the market by giving the impresssion the Board do not know what to do.

As alluded to before, the SP should not be sold off like this when we are told we are on the brink of rolling out Peer reviewed Promarker D tests in many counties where rebate codes are not an issue. The reality seems, very few tests are done ( if any), even though the benefits in health and cost savings is beyond doubt we are told. Something does not add up. It is more than Covid tests jaming up analytical labs, it must be, afterall, Covid is going to be with us for many many years l think. One thing that does inspire confidence is the highly likely fact that even if management are dunder heads, PIQ will present as a very attractive take over target to many players in this space, so l genuinely believe lots of unrealised value is held in the company. This is why l remain loyal.